Auriga Upgrades Protalix BioTherapeutics (PLX) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall St treads water as chips rise, megacaps fall ahead of Fed, Big Tech earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise about 2% as Yemen fighting stokes supply fears
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.60 +2.77%
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 16 | New: 17
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 16 | New: 17
Join SI Premium – FREE
Auriga upgraded Protalix BioTherapeutics (NYSE: PLX) from Hold to Buy, price target raised from $8 to $9.
For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $6.73 yesterday.
For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $6.73 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Verizon (VZ) to Buy
- Armstrong World Industries (AWI) PT Lowered to $200 at DA Davidson
- Freedom Broker Upgrades Piedmont Office Realty Trust (PDM) to Buy
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesRelated Entities
AurigaSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
